Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 23;2016(1):CD011732.
doi: 10.1002/14651858.CD011732.pub2.

Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer

Chumnan Kietpeerakool  1 , Amornrat Supoken, Malinee Laopaiboon, Pisake Lumbiganon
Affiliations

Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer

Chumnan Kietpeerakool et al. Cochrane Database Syst Rev. .

Abstract

Background: Ovarian cancer is the third most common gynaecological cancer worldwide, with an age-standardised incidence rate of 6.1 per 10,000 women. Standard therapy for advanced epithelial ovarian cancer (EOC) includes a combination of cytoreductive surgery and platinum-based chemotherapy. Cytoreductive surgery aims to remove as much of the visible tumour as possible. As extensive intraperitoneal metastases are typical of advanced EOC, cytoreductive surgery is usually an extensive procedure with the risk of excessive bleeding. Tranexamic acid given perioperatively is effective in reducing blood loss and allogeneic blood transfusion requirements in a variety of surgical settings. Therefore, tranexamic acid seems to be a promising agent for minimising blood loss and the need for blood transfusion among women with advanced EOC undergoing cytoreductive surgery.

Objectives: To assess the effects of tranexamic acid for reducing blood loss associated with cytoreductive surgery in women with advanced EOC (stage III to IV).

Search methods: We searched the Cochrane Gynaecological, Neuro-oncology and Orphan Cancers Trial Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 5, 2015), MEDLINE, EMBASE and conference proceedings to May 2015. We also checked registers of clinical trials, citation lists of included studies, key textbooks and previous systematic reviews for potentially relevant studies.

Selection criteria: We included randomised controlled trials (RCTs) comparing tranexamic acid given during surgery versus placebo or no treatment, in adult women diagnosed with advanced EOC.

Data collection and analysis: Two review authors (CK, AS) independently selected potentially relevant trials, extracted data, assessed risk of bias, compared results and resolved disagreements by discussion.

Main results: We found only one study that met our inclusion criteria. This was a randomised double blind, placebo-controlled multicentre study conducted to evaluate the effectiveness of a single dose of intravenous tranexamic acid (15 mg/kg body weight) versus placebo, given immediately before surgery for reducing blood loss and the need for red blood cell transfusion. The mean total estimated blood loss was 668.34 mL and 916.93 mL for participants assigned to tranexamic acid and placebo groups, respectively. The mean difference (MD) of total estimated blood loss between the groups did not show a clinically important effect (MD - 248.59 mL; 95% confidence interval (CI) - 550.9 to 53.79; one study, 100 participants; moderate quality evidence). The mean number of transfused units of blood components was not different between the two groups (low quality evidence). There were no noted differences in the incidence of reoperation, readmission or thromboembolic events (very low quality evidence). We considered the methodology of the included study to be at low risk of selection, detection, and reporting biases. However, we were concerned about an imbalance of some baseline characteristics between the groups, and as there was no protocol for blood transfusion, the rate of blood transfusion may vary depending on the practice of each participating hospital.

Authors' conclusions: Currently, there is insufficient evidence to recommend the routine use of tranexamic acid for reducing blood loss in women undergoing cytoreductive surgery for advanced EOC, as only limited data are available from a single, low quality RCT at low overall risk of bias.

PubMed Disclaimer

Conflict of interest statement

Chumnan Kietpeerakool: none known. Amornrat Supoken: none known. Malinee Laopaiboon: none known. Pisake Lumbiganon: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Estimated total blood loss (mL), Outcome 1 Estimated total blood loss (mL).
2.1
2.1. Analysis
Comparison 2 Number of transfused units of blood components, Outcome 1 Number of transfused units of RBC.
2.2
2.2. Analysis
Comparison 2 Number of transfused units of blood components, Outcome 2 Number of transfused units of plasma.
3.1
3.1. Analysis
Comparison 3 Rate of blood component transfusion, Outcome 1 Red blood cell transfused women.
3.2
3.2. Analysis
Comparison 3 Rate of blood component transfusion, Outcome 2 Plasma transfused women.
4.1
4.1. Analysis
Comparison 4 Incidence of reoperation, Outcome 1 Reoperation.
5.1
5.1. Analysis
Comparison 5 Incidence of readmission, Outcome 1 Readmission.
6.1
6.1. Analysis
Comparison 6 Incidence of thromboembolic events, Outcome 1 Venous thromboembolic events.
6.2
6.2. Analysis
Comparison 6 Incidence of thromboembolic events, Outcome 2 Arterial thromboembolic events.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD011732

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Lundin 2014 {published data only}
    1. Lundin ES, Johansson T, Zachrisson H, Leandersson U, Bäckman F, Falknäs L, et al. Single‐dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double‐blind placebo‐controlled randomized multicenter study. Acta Obstetricia et Gynecologica Scandinavica 2014;93(4):335‐44. - PubMed

References to studies excluded from this review

Celebi 2006 {published data only}
    1. Celebi N, Celebioglu B, Selcuk M, Canbay O, Karagoz AH, Aypar U. The role of antifibrinolytic agents in gynecologic cancer surgery. Saudi Medical Journal 2006;27(5):637‐41. - PubMed

Additional references

Chi 2012
    1. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao M, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC‐NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecologic Oncology 2012;124(1):10‐4. - PubMed
CTCAE 2010
    1. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03. National Institutes of Health, US Department of Health and Human Services 2010; publication no. 09‐7473 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm).
De Oliveira 2012
    1. Oliveira GS Jr, Schink JC, Buoy C, Ahmad S, Fitzgerald PC, McCarthy RJ. The association between allogeneic perioperative blood transfusion on tumour recurrence and survival in patients with advanced ovarian cancer. Transfusion Medicine 2012;22(2):97‐103. - PubMed
Deeks 2001
    1. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. - PubMed
Gadducci 1994
    1. Gadducci A, Baicchi U, Marrai R, Bravo B, Fosella PV, Facchini V. Pretreatment plasma levels of fibrinopeptide‐A (FPA), D‐dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecologic Oncology 1994;53(3):352‐6. - PubMed
GLOBOCAN 2012
    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11. International Agency for Research on Cancer, 2013. Available from: http://globocan.iarc.fr (accessed 6 November 2014).
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. British Medical Journal 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at www.cochrane‐handbook.org.
Jemal 2008
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 2008;58(2):71‐96. - PubMed
Kaku 2003
    1. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, et al. Histological classification of ovarian cancer. Medical Electron Microscopy 2003;36(1):9‐17. - PubMed
Ker 2013
    1. Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD010562.pub2] - DOI - PubMed
Kjølhede 2015 [pers comm]
    1. Kjølhede P. Request for information of published article ‏[personal communication]. Email to: P Kjølhede 22 June 2015.
Koh 2006
    1. Koh SC, Khalil R, Lim FK, Ilancheran A, Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and D‐dimer levels and survival outcome by 36 months from ovarian cancer. Clinical and Applied Thrombosis/Hemostasis 2006;12(1):3‐8. - PubMed
Kongnyuy 2014
    1. Kongnyuy E, Wiysonge C. Interventions to reduce haemorrhage during myomectomy for fibroids. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD005355.pub5] - DOI - PMC - PubMed
Kvolik 2010
    1. Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas‐Obrovac L. An overview of coagulation disorders in cancer patients. Surgical Oncology 2010;19(1):e33‐46. - PubMed
Liberati 2009
    1. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. - PMC - PubMed
McCormack 2012
    1. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012;72(5):585‐617. - PubMed
Novikova 2015
    1. Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD007872.pub3] - DOI - PMC - PubMed
Perel 2013
    1. Perel P, Ker K, Morales Uribe CH, Roberts I. Tranexamic acid for reducing mortality in emergency and urgent surgery. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD010245.pub2] - DOI - PMC - PubMed
Prat 2015
    1. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. Journal of Gynaecology Oncology 2015;26(12):87‐9. - PMC - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Roberts 2015
    1. Ker K, Roberts I, Shakur H, Coats T. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD004896.pub4] - DOI - PMC - PubMed
Schiergens 2015
    1. Schiergens TS, Rentsch M, Kasparek MS, Frenes K, Jauch KW, Thasler WE. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Diseases of the Colon & Rectum 2015;58(1):74‐82. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Sitalakshmi 2008
    1. Sitalakshmi S, Rameshkumar K, Damodar P. Significance of haemostatic markers in ovarian carcinoma. Indian Journal of Medical & Paediatric Oncology 2008;29(2):6‐10.
Sterne 2011
    1. Sterne J, Sutton A, Loannidis J, Terrin N, Jones D, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ 2011;343:d4002. - PubMed
Vergote 2010
    1. Vergote I, Tropé C, Amant F, Kristensen G, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 2010;363(10):943‐53. - PubMed

Publication types

MeSH terms